These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 6239574)
1. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Fahey MR; Rupp SM; Fisher DM; Miller RD; Sharma M; Canfell C; Castagnoli K; Hennis PJ Anesthesiology; 1984 Dec; 61(6):699-702. PubMed ID: 6239574 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Eastwood NB; Boyd AH; Parker CJ; Hunter JM Br J Anaesth; 1995 Oct; 75(4):431-5. PubMed ID: 7488483 [TBL] [Abstract][Full Text] [Related]
3. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. Smith CE; van Miert MM; Parker CJ; Hunter JM Anaesthesia; 1997 Sep; 52(9):833-41. PubMed ID: 9349062 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. Chow B; Bowden MI; Ho E; Weatherley BC; Bion JF Br J Anaesth; 2000 Dec; 85(6):850-5. PubMed ID: 11732518 [TBL] [Abstract][Full Text] [Related]
6. Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. Shi WZ; Fahey MR; Fisher DM; Miller RD; Canfell C; Eger EI Anesthesiology; 1985 Dec; 63(6):584-8. PubMed ID: 2932981 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. De Wolf AM; Freeman JA; Scott VL; Tullock W; Smith DA; Kisor DF; Kerls S; Cook DR Br J Anaesth; 1996 May; 76(5):624-8. PubMed ID: 8688259 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. Vandenbrom RH; Wierda JM; Agoston S Clin Pharmacokinet; 1990 Sep; 19(3):230-40. PubMed ID: 2394062 [TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics. Farenc C; Audran M; Lefrant JY; Mazerm I; Bressolle F J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):117-26. PubMed ID: 10202964 [TBL] [Abstract][Full Text] [Related]
10. Effect of age on cis-atracurium besylate pharmacokinetics following a single 1 mg kg Aguilar A; Andaluz A; Moll X; Cristòfol C; García F Vet Anaesth Analg; 2019 Sep; 46(5):643-651. PubMed ID: 31155378 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Boyd AH; Eastwood NB; Parker CJ; Hunter JM Br J Anaesth; 1996 Mar; 76(3):382-8. PubMed ID: 8785138 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. Ward S; Boheimer N; Weatherley BC; Simmonds RJ; Dopson TA Br J Anaesth; 1987 Jun; 59(6):697-706. PubMed ID: 3606914 [TBL] [Abstract][Full Text] [Related]
13. Neuromuscular effects of atracurium during halothane-nitrous oxide and enflurane-nitrous oxide anesthesia in humans. Rupp SM; McChristian JW; Miller RD Anesthesiology; 1985 Jul; 63(1):16-9. PubMed ID: 3160265 [TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic-pharmacodynamic model for a muscle relaxant: atracurium. Nigrovic V; Gaspari J; Banoub M Eur J Clin Pharmacol; 1996; 49(4):325-32. PubMed ID: 8857080 [TBL] [Abstract][Full Text] [Related]
15. Effect of renal failure on laudanosine excretion in man. Fahey MR; Rupp SM; Canfell C; Fisher DM; Miller RD; Sharma M; Castagnoli K; Hennis PJ Br J Anaesth; 1985 Nov; 57(11):1049-51. PubMed ID: 3840380 [TBL] [Abstract][Full Text] [Related]
16. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Varin F; Ducharme J; Théorêt Y; Besner JG; Bevan DR; Donati F Clin Pharmacol Ther; 1990 Jul; 48(1):18-25. PubMed ID: 2369806 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. deBros FM; Lai A; Scott R; deBros J; Batson AG; Goudsouzian N; Ali HH; Cosimi AB; Savarese JJ Anesth Analg; 1986 Jul; 65(7):743-6. PubMed ID: 3755015 [TBL] [Abstract][Full Text] [Related]
18. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Bion JF; Bowden MI; Chow B; Honisberger L; Weatherley BC Intensive Care Med; 1993; 19 Suppl 2():S94-8. PubMed ID: 8106686 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome. Lefrant JY; Farenc C; De la Coussaye JE; Muller L; Ripart J; Cuvillon P; Saissi G; Eledjam JJ Anaesth Intensive Care; 2002 Aug; 30(4):422-7. PubMed ID: 12180578 [TBL] [Abstract][Full Text] [Related]
20. Inactivation of atracurium in human and rat plasma. Nigrovic V; Pandya JB; Auen M; Wajskol A Anesth Analg; 1985 Nov; 64(11):1047-52. PubMed ID: 2932037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]